Current Edition

CPhI Worldwide Advisory Board returns with five new global experts

Board helps to steer the overall development of CPhI events and content
Amsterdam, 8th May 2017: CPhI Worldwide, organised by UBM EMEA, announces its Advisory Board for 2017.
The new board features some of the industry’s most experienced and well-respected executives, consultants and experts, and is designed to bring a wealth of experience to help shape the agenda at the eponymous CPhI Worldwide event – taking place this year in Frankfurt, Germany (24-26 October, 2017 at the Messe Frankfurt).
The board also helps navigate improvements to the event’s co-located zones and sessions, as well identifying future opportunities and the industry’s current hot topics.
This year, the advisory board welcomes five new high-profile members: Jim Miller, President of PharmSource; Rita Peters, Editorial Director of Pharmaceutical Technology, Pharmaceutical Technology Europe and BioPharm International; Peter Schmitt, President of Montesino; Claudia Lin, General Manager at AlphaMab; and Kate Kuhrt, Head of GTM Life Sciences, Clarivate Analytics.
Jim Miller joins the board on the back of the internationally renowned industry analysis he provides to global pharma and contract services companies through his consultancy, PharmSource. Mr Miller is one of the most influential and respected experts in bio/pharmaceutical outsourcing, and regularly speaks at pharma events and is a member of several editorial boards.
Another prominent industry analyst to join the board is Kate Kuhrt, a leading authority on the global API and generics markets, and pharma product launches. She has two decades of experience in covering the industry and is a speaker and adviser to some of the world’s largest pharma companies. Her specialities include emerging biopharma segments and rapid growth markets.
Peter Schmitt will be utilizing over 30 years of industry experience to provide invaluable global insights into the packaging sector. In 1996, he founded Montesino Associates, followed in 2000 by Montesino Technologies. Mr. Schmitt will be leveraging his knowledge to offer insights across M&A and industry consolidation, regulatory initiatives such as serialization, track and trace, Type III Drug Master Files, sustainability, OEE, new materials and technology, and the ever-present challenge of cost optimization.
Bringing knowledge from the Chinese R&D industry is Dr. Claudia Lin, General Manager at AlphaMab Co. Ltd – a leading Chinese biotech company known for its excellent R&D capabilities. Prior to AlphaMab, Dr. Lin was Head of Quality for Innovent Biologics in China, where she built the company’s international standard GMP capabilities from the ground up. Over her career, Dr. Lin has demonstrated a passion for women’s leadership in the industry, and is both a mentor and a leading voice on furthering women in senior roles across pharma.
The final new panellist for 2017 is Rita Peters, Editorial Director of Pharmaceutical Technology, Pharmaceutical Technology Europe and BioPharm International, who brings her decade long experience of editing three of the industry’s biggest publications. Ms. Peters is a leading producer of industry thought-leadership and has a wide ranging global knowledge having covered many of the biggest stories, new technology developments and trends of the last 10-years.
These new members will join together with the seven current members of the expert panel Dilip G. Shah, CEO of Vision Consulting; Alan Sheppard, Principal of Global Generics and Biosimilars at QuintilesIMS; Martin Folger, Head of Global CMC Development – Pharmaceuticals at Boehringer Ingelheim Vetmedica GmbH; Nigel Walker, Managing Director of That’s Nice; Roger Bakale, Vice President of CMC and Clinical Supply Chain at Receptos; Jan Ramakers, Owner of Fine Chemical Consulting Group; Will Downie, Senior Vice President of Global Sales & Marketing, Catalent Pharma Solutions.
“CPhI Worldwide has firmly asserted itself as the leading global platform for doing business and finding new opportunities in the worldwide pharmaceutical community. We are really delighted to be able to call upon such a unique mix of industry experts to provide such invaluable insights into hot topics within the industry, alongside an abundance of knowledge and experience. We now look to further enhance the new opportunities and services we bring to our customers”, Orhan Caglayan, Brand Director at UBM EMEA.
For more information on the advisory board’s role at CPhI, please visit